The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis

Digestive Diseases and Sciences

Volumn 50, Issue 9, 2005, Pages 1734-1740

  Levy, Cynthia ^a   Lymp, James ^b   Angulo, Paul ^b   Gores, Gregory J ^a   Larusso, Nicholas ^b   Lindor, Keith D ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

Biliary tract malignancy; Carbohydrate 19 9; Cholangiocarcinoma; Primary sclerosing cholangitis

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BILE DUCT NEOPLASMS; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 23944440978     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2927-8     Document Type: Article

References (22)

1. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):VI1-VI9, 2002
2. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33(6): 1353-1357, 2001
3. Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 10(Suppl 4):308-311, 1999
4. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, Jr, LaRusso NF: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213(1):21-25, 1991
5. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38(4):610-615, 1996
6. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E: Primary sclerosing cholangitis: A long-term follow-up study. Scand J Gastroenterol 22(6):655-664, 1987
7. Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study. Hepatology 27(2):311-316, 1998
8. Broome U, Lofberg R, Veress B, Eriksson LS: Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 22(5): 1404-1408, 1995
9. Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, Abu-Elmaagd K, Madariaga JR, Slivka A, Martini J: Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 56(1):40-47, 2002
10. Rogers SA, Podolsky DK: Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: An analysis of the serological marker CA 19-9. Hepatology 19(2):543-545, 1994
11. Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA: CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg 1(2):94-98, 1995
12. Reeves ME, DeMatteo RP: Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 19(2):84-93, 2000
13. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA: The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35(Pt 1):99-103, 1998
14. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE, Jr.: Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68(9):874-879, 1993
15. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108(3):865-869, 1995
16. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H: Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 31(1):7-11, 2000
17. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204-207, 2000
18. Bjornsson E, Kilander A, Olsson R: CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19(6):501-508, 1999
19. Hultcrantz R, Olsson R, Danielsson A, Jamerot G, Loof L, Ryden BO, Wahren B, Broome U: A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 30(4):669-673, 1999
20. Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26(5):474-479, 2000
21. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R: Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 15(3):226-230, 2000
22. Fletcher R, Fletcher S, Wagner E: Clinical Epidemiology: The Essenctials. Third ed. Philadelphia: Williams & Williams, 1996.